Ovine conceptus secretory proteins and bovine recombinant interferon alpha (1)-1 decrease endometrial oxytocin receptor concentrations in cyclic and progesterone-treated ovariectomized ewes.
A series of experiements was performed to determine whether proteins produced by the sheep conceptus (oCSP) during the time of maternal recognition of pregnancy or bovine recombinant interferon alpha 1-1 (brIFN) decrease oxytocin receptor concentrations in the endometrium of cyclic or ovariectomized progesterone-treated ewes. In experiment 1, cyclic ewes received intrauterine infusions of serum proteins (oSP), oCSP or brIFN on days 12, 13 and 14 of the oestrous cycle. Ewes then received an oxytocin challenge (1 microgram in 0.9% NaCl), and blood samples were taken just before and every 10 min for 1 h after the challenge; these were measured for 13,14-dihydro-15-ketoprostaglandin F 2 alpha (PGFM), the stable metabolite of prostaglandin F 2 alpha. Endometrial oxytocin receptor concentrations were then measured. The oCSP and brIFN treatments suppressed both endometrial oxytocin receptor concentrations and oxytocin-induced increases in PGFM concentrations. In experiment 2, ewes were ovariectomized and then pretreated with a fluorogestone acetate-releasing intravaginal device for 10 days followed by oestradiol (25 micrograms i.m. twice daily for 2 days). Ewes were then treated with progesterone (10 mg i.m. twice daily for 12 days). Ewes received intrauterine infusions of oSP, oCSP and brIFN on days 10, 11 and 12 of progesterone treatment. On the day after the last progesterone treatment, ewes were challenged with oxytocin and blood samples collected to measure PGFM. Endometrial oxytocin receptors were also measured. Treatment with oCSP, but not brIFN, suppressed endometrial concentrations of oxytocin receptor, and neither oCSP nor brIFN altered oxytocin-induced increases in PGFM concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)
Vallet
J L
JL
AFRC Research Group on Hormones and Farm Animal Reproduction, University of Nottingham, Sutton Bonington, Loughborough.
Lamming
G E
GE
D000818:Animals; D002417:Cattle; D003864:Depression, Chemical; D015237:Dinoprost / Q000378:metabolism; D004717:Endometrium / Q000187:drug effects*; D004971:Estrus; D005260:Female; D005326:Fetal Proteins / Q000494:pharmacology*; D007370:Interferon Type I / Q000494:pharmacology*; D010052:Ovariectomy; D010121:Oxytocin / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D011945:Receptors, Angiotensin / Q000187:drug effects*; D018045:Receptors, Oxytocin; D011994:Recombinant Proteins; D012756:Sheep / Q000378:metabolism*
D005326:Fetal Proteins; D007370:Interferon Type I; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; D011994:Recombinant Proteins; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost